Iovance Biotherapeutics Investor Presentation — May 2022

Document content

© 2022, Iovance Biotherapeutics, Inc.Corporate Overview

© 2022, Iovance Biotherapeutics, Inc.Forward -Looking Statements

Certain matters discussed in this presentation are “forward- looking statements” of Iovance Biotherapeutics, Inc. (hereinafter re ferred to as the “Company,” “we, ” “us, ” or “our”)

within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All such written or oral statements made in this presentation, other than statements of

historical fact, are forward- looking statements and are intended to be covered by the safe harbor for forward- looking statements provided by the PSLRA. Without limiting the

foregoing, we may, in some cases, use terms such as “predicts, ” “believes,” “potential,” “continue,” “estimates,” “anticipate s,”“expects, ” “plans,” “intends,” “forecast,”

“guidance,” “outlook,” “may, ” “could, ” “might,” “will, ” “should” or other words that convey uncertainty of future events or o utcomes and are intended to identify forward- looking

statements. Forward -looking statements are based on assumptions and assessments made in light of management’s experience and per ception of historical trends, current

conditions, expected future developments and other factors believed to be appropriate. Forward- looking statements in this press release are made as of the date of this press

release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future eve ntsor otherwise. Forward- looking statements are

not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of ourcontrol, that may cause actual results, levels of

activity, performance, achievements and developments to be materially different from those expressed in or implied by these f orward -looking statements. Important factors that

could cause actual results, developments and business decisions to differ materially from forward- looking statements are describ ed in the sections titled “Risk Factors“ in our

filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10 -K and Quarterly Reports on Form 10 -Q, and include, but are not

limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and

our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulator y authority approval of, or other action with respect

to, our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA appr oval; preliminary and interim clinical results, which